Verona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, expectations were $-0.5. Operator: Good morning, everyone, and welcome to Verona Pharma’s Third Quarter 2024 Financial Results and Operating Highlights Conference Call.
Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 years
Verona Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
Verona Pharma Q3 2024 Earnings Preview
Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.
Verona Pharma Reports Strong Q3 Launch for COPD Drug
Verona Pharma ( (VRNA) ) has released its Q3 earnings. Here is a breakdown of the information Verona Pharma presented to its investors. Verona
Raleigh pharma's stock hits record high amid drug launch
Verona Pharma's market cap nears $3 billion after drug launch. Ohtuvayre sales reached $5.6 million in the third quarter. Over 5,000 Ohtuvayre prescriptions filled by October's end. A Raleigh biopharmaceutical company is nearing a $3 billion market capitalization amid the launch of its lead drug.
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique
Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 ...
pharmaphorum1d
Verona cuts $400m loan deal as it preps COPD drug for market
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine ...